About This Stock
More About This Stock
How Will Biotech ETFs React To These Q4 Earnings Releases?
Article By:
Zacks Investment Research
Saturday, February 6, 2021 4:47 PM EDT
Any positive news highlighting the progress of vaccine or antibody manufacturers is expected to create great returns for investors. Let’s take a look at some biotechnological earnings releases to see if these will impact ETFs exposed to the space.
AstraZeneca To Buy Rare-Disease Specialist Drugmaker Alexion For $39 Billion
Article By:
Benzinga
Saturday, December 12, 2020 12:07 PM EDT
AstraZeneca plc has announced it will buy Alexion Pharmaceuticals, Inc. for $39 billion. AstraZeneca and Alexion said this morning that their boards unanimously approved the deal. It is expected to close in the third quarter of 2021.
Alexion Pharmaceuticals: Growth At A Reasonable Price (GARP)
Article By:
Chuck Carnevale
Friday, July 10, 2020 2:02 PM EDT
It very interesting that Alexion Pharmaceuticals Inc. after going public in 2001, did not generate their first profit until December 2008. As we all know, this was in the throes of what is now known as the Great Recession of 2008.
In this article: ALXN
Are Biotech ETFs In Trouble As Coronavirus Dims Guidance?
Article By:
Zacks Investment Research
Saturday, May 9, 2020 7:49 PM EDT
Although the coronavirus seems to be opening up opportunities for biotech companies, it is dampening their guidance as well. Despite impressive results, most of these biotechs have been seeing declining share prices since the earnings releases.
Biotech M&A Deal Looks Too Rich For Its Blood
Article By:
Lipper Alpha Insight
Wednesday, May 6, 2020 10:46 AM EDT
Alexion Pharmaceuticals (ALXN) is either buying Portola Pharmaceuticals (PTLA) on the cheap at $1.4 billion, or paying a whopping premium – it all depends on your starting date.
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By:
T.J. Hayes
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Biotech ETFs In Focus On String Of Q2 Earnings Beats
Article By:
Zacks Investment Research
Sunday, August 12, 2018 4:27 PM EDT
The biotech sector has been performing remarkably well driven by a wave of mergers and acquisitions, new tax legislation, and a positive regulatory backdrop. Strong Q2 earnings results have added to the strength as biotech giants topped estimates.
